UK market access Archives -

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Despite the UK’s

Global comparator data signal “alarm bells” for UK Government, says APBI

https://pharmaphorum.com/market-access-2/global-comparator-data-signal-alarm-bells-for-uk-government-says-apbi/

Debates/ Market Access/ Views & Analysis/ Views and analysis/ Webinars/ Webinars in home page/ Webinars On demand

ICSs – an opportunity to improve Patient & Market Access at a local level

mike.hammerton@pharmaphorum.com integrated care systems, IQVIA, market access, NHS, NHS legislation, UK market access 0 Comment

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in

ICSs – an opportunity to improve Patient & Market Access at a local level

https://pharmaphorum.com/webinars/integrated-care-systems-opportunity-to-improve-patient-market-access/

Articles/ Cancer/ Healthcare/ Market Access/ Pharma Market Access/ UK & Europe/ Views & Analysis/ Views and analysis

NHS England takes charge on market access

Andrew McConaghie NHS England, UK market access 0 Comment

Today sees patients gain full NHS access to breast cancer drug Perjeta, a full six years on from its initial

NHS England takes charge on market access

https://pharmaphorum.com/views-analysis-market-access/perjeta-benefits-nhs-england-takes-charge/

Cancer/ News/ News/ News/ Oncology/ Pharma Market Access/ R&D/ UK & Europe

BI drug named Promising Innovative Medicine in mesothelioma

Andrew McConaghie Boehringer Ingelheim, Early Access to Medicines Scheme, mesothelioma, MHRA, Promising Innovative Medicine, UK market access, Vargatef 0 Comment

Boehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for

BI drug named Promising Innovative Medicine in mesothelioma

https://pharmaphorum.com/news/bi-drug-named-promising-innovative-medicine-mesothelioma/

News/ Pharma Market Access/ Top stories/ UK & Europe

Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma

Richard Staines blood cancer, cancer, Cancer Drugs Fund, Johnson & Johnson, mantle cell lymphoma, UK market access 0 Comment

NICE suggests interim CDF funding while further data is gathered.

Janssen’s Imbruvica runs into trouble with NICE in mantle cell lymphoma

https://pharmaphorum.com/news/imbruvica-mantle-cell-lymphoma/

News/ Pharma Market Access/ Top stories/ UK & Europe

Sanofi’s blockbuster-tipped Dupixent set for European launches

Andrew McConaghie atopic dermatitis, inflammation and immunology, Sanofi, UK market access 0 Comment

Sanofi’s new atopic dermatitis treatment Dupixent has gained EU approval, setting it up for a launch across key

Sanofi’s blockbuster-tipped Dupixent set for European launches

https://pharmaphorum.com/news/sanofis-blockbuster-tipped-dupixent-set-european-launches/

Cancer/ News/ Pharma Market Access/ UK & Europe

After a year’s delay, BMS seals Opdivo lung cancer deal with NICE

Richard Staines Bristol-Myers Squibb, cancer, Cancer Drugs Fund, lung cancer, market access, NICE, UK market access 0 Comment

Bristol-Myers Squibb will now challenge its rival, MSD’s Keytruda, in second line lung cancer treatment in England after

After a year’s delay, BMS seals Opdivo lung cancer deal with NICE

https://pharmaphorum.com/news/lung-cancer-patients-england-get-opdivo-bms-deal-nice/

Cancer/ Healthcare/ News/ UK & Europe

Roche hails 4 year NICE access deal for Gazyvaro

Andrew McConaghie Cancer Drugs Fund, Gazyvaro, Roche UK, UK market access 0 Comment

NICE has agreed a deal with Roche on its new follicular lymphoma treatment Gazyvaro, giving the drug up

Roche hails 4 year NICE access deal for Gazyvaro

https://pharmaphorum.com/news/roche-hails-4-year-nice-access-deal-gazyvaro/

Articles/ Healthcare/ UK & Europe/ Views and analysis

Will UK patients get access to novel drugs?

Andrew McConaghie NHS England, NICE, Quintiles IMS Market Access Summit, quintilesIMS, UK market access 0 Comment

Access to new medicines is not high up the list of priorities for NHS England, but pharma must seize opportunities to promote innovation uptake.

Will UK patients get access to novel drugs?

https://pharmaphorum.com/views-and-analysis/will-uk-patients-get-access-to-novel-drugs/

Trending

UK market access

Login